Niagen Bioscience Inc
OCD1
Company Profile
Business description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Contact
10900 Wilshire Boulevard
Suite 600
Los AngelesCA90024
USAT: +1 310 388-6706
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
117
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
Investors too optimistic about overvalued ASX share
Upgraded first-half revenue guidance at the upper end of the previously announced range.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.10 | 33.50 | -0.37% |
| CAC 40 | 7,921.68 | 83.19 | 1.06% |
| DAX 40 | 25,645.04 | 340.62 | 1.35% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,752.88 | 19.88 | 0.19% |
| HKSE | 22,971.93 | 679.94 | -2.87% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 63,330.92 | 1,290.32 | -2.00% |
| NZX 50 Index | 13,746.84 | 14.45 | -0.11% |
| S&P 500 | 7,757.17 | 44.60 | 0.58% |
| S&P/ASX 200 | 8,798.30 | 33.00 | -0.37% |
| SSE Composite Index | 3,679.86 | 33.17 | -0.89% |